Evaluation of recombinant interleukin-2 immunotherapy for human hemangiosarcoma in a SCID mice model (WB-SCID).
We treated the patients with cutaneous hemangiosarcoma with recombinant interleukin-2 (rIL-2) immunotherapy that showed clear therapeutic effects. This immunotherapy is popular for the treatment of hemangiosarcoma in Japan. The purpose of this study is to clarify the clinical effects in an animal experiment. After establishing a SCID mouse model of human hemangiosarcoma WB-SCID, we used this model to investigate anti-tumor effects of rIL-2 and LAK cells. We demonstrated that hemangiosarcoma cells are LAK-sensitive, and LAK cells induced by rIL-2 suppress the growth of hemangiosarcoma. Our results may assure the clinical effects of rIL-2 immunotherapy on hemangiosarcoma.
Masuzawa
M
M
Department of Dermatology, School of Medicine, Kitasato University, Sagamihara-shi, Kanagawa-ken 228-8555, Japan. mikio@med.kitasato-u.ac.jp
Mochida
N
N
Amano
T
T
Fujimura
T
T
Hamada
Y
Y
Tamauchi
H
H
Sakurai
Y
Y
Nishiyama
S
S
Katsuoka
K
K
D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D003602:Cytotoxicity, Immunologic; D005260:Female; D006394:Hemangiosarcoma / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000627:therapeutic use*; D007564:Japan; D015979:Killer Cells, Lymphokine-Activated; D051379:Mice; D016513:Mice, SCID; D011994:Recombinant Proteins / Q000627:therapeutic use; D012535:Scalp; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D014183:Transplantation, Heterologous
D007376:Interleukin-2; D011994:Recombinant Proteins